Patent: 10,010,587
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Summary for Patent: 10,010,587
Title: | IL-2R.beta.-selective agonists in combination with an anti-CTLA-4 antibody or an anti-PD-1 antibody |
Abstract: | The invention relates to (among other things) method of administering to a patient suffering from a cancer, the method comprising the steps of: (a) an IL-2R.beta.-activating amount of a long acting, IL-2R.beta.-selective agonist; and (b) a CTLA-4 pathway-inhibiting amount of an anti-CTLA-4 antibody or a PD-1 pathway-inhibiting amount of an anti-PD-1 antibody. |
Inventor(s): | Addepalli; Murali Krishna (Secunderabad, IN), Charych; Deborah H. (Albany, CA), Kantak; Seema (Pacifica, CA), Lee; Steven Robert (San Leandro, CA) |
Assignee: | Nektar Therapeutics (San Francisco, CA) |
Application Number: | 15/120,214 |
Patent Claims: | see list of patent claims |
Details for Patent 10,010,587
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Clinigen, Inc. | PROLEUKIN | aldesleukin | For Injection | 103293 | 05/05/1992 | ⤷ Try a Trial | 2034-02-21 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |